Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of DC-TAB in healthy volunteers
NL-OMON34913Phase 1Active, not recruiting
- Sponsor
- Delta Crystallon BV
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of decitabine in multiple sclerosis (MS) (4 arms), sponsored by Delta Crystallon BV. Primary endpoint: Safety and tolerability after single and repeated dosing. Started Dec 2009; status: active, not recruiting.
02
Drugs
decitabine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON34913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34913.